Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 601,700 shares, an increase of 532.0% from the June 30th total of 95,200 shares. Based on an average daily trading volume, of 320,700 shares, the short-interest ratio is currently 1.9 days. Currently, 0.5% of the company’s stock are sold short.

Indivior Price Performance

Shares of INDV stock traded up $2.21 on Thursday, reaching $13.09. The company’s stock had a trading volume of 1,700,243 shares, compared to its average volume of 224,124. The company has a market capitalization of $1.80 billion, a P/E ratio of 1,309.00 and a beta of 0.69. Indivior has a 12-month low of $9.14 and a 12-month high of $24.39. The stock’s 50 day simple moving average is $15.17 and its 200-day simple moving average is $17.66. The company has a quick ratio of 0.74, a current ratio of 0.92 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million during the quarter, compared to analysts’ expectations of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%. As a group, equities analysts predict that Indivior will post 1.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Piper Sandler began coverage on Indivior in a report on Tuesday. They set an “overweight” rating and a $22.00 price target on the stock. Craig Hallum reduced their price target on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th.

Institutional Investors Weigh In On Indivior

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Indivior by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock valued at $134,875,000 after purchasing an additional 90,673 shares during the last quarter. Norges Bank purchased a new position in shares of Indivior during the fourth quarter worth approximately $36,011,000. UBS Group AG lifted its holdings in shares of Indivior by 71.9% in the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock worth $12,615,000 after acquiring an additional 345,556 shares during the last quarter. Renaissance Group LLC boosted its stake in shares of Indivior by 6.1% in the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock valued at $1,573,000 after purchasing an additional 5,896 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Indivior during the 4th quarter valued at $649,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.